Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. - Wikidata - wikimedia - TriplyDB

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

http://www.wikidata.org/entity/Q35250682

about

Long lasting inhibitors of the gastric H,K-ATPase Proton pump inhibitors exert anti-allergic effects by reducing TCTP secretion.Multivariate analysis of pathophysiological factors in reflux oesophagitis.Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis.Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings.Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects.Meta-analysis of the effect of placebo on the outcome of medically treated reflux esophagitis.Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease.Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis.What is heartburn worth? A cost-utility analysis of management strategies Esomeprazole tablet vs omeprazole capsule in treating erosive esophagitis.Progress with proton pump inhibition.Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.Management of Asymptomatic Erosive Esophagitis: An E-Mail Survey of Physician's Opinions.The knife or the pill in the long-term treatment of gastroesophageal reflux disease?Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis Gastroprotective effect of the three glucuronopyranoside flavonoids in rats.Overlap of functional dyspepsia and GERD--diagnostic and treatment implications.The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment.Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn.Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis.Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice.pH, healing rate and symptom relief in acid-related diseases.Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Famotidine Erosive Esophagitis Study Group.Antileishmanial activity of the antiulcer agent omeprazole.Medical management of esophageal reflux.Management of refractory and complicated reflux esophagitis.Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.Protective Effect of ECQ on Rat Reflux Esophagitis Model.Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.The Inhibitory Effect of Quercetin-3-O-beta-D-Glucuronopyranoside on Gastritis and Reflux Esophagitis in Rats Acid control with esomeprazole and lansoprazole: a comparative dose-response study.Comparison of IY81149 with omeprazole in rat reflux oesophagitis.Distension during gastroesophageal reflux: effects of acid inhibition and correlation with symptoms.The effect of synthetic ceramide analogues on gastritis and esophagitis in rats.Laryngeal epithelial defenses against laryngopharyngeal reflux: investigations of E-cadherin, carbonic anhydrase isoenzyme III, and pepsin.

P2860

Q28299927-9BF51B2F-F02D-4D01-BBF3-5FABB7392D9E Q33457175-9E007EB6-92E1-462D-9EAA-40541996CCB5 Q33617730-05D1D901-C8FA-46AC-9D45-DC92AA3E8500 Q33624127-F8DE2669-ED08-468E-A27A-867BE9560F2E Q33898666-F5D84AD0-BA99-435C-A092-B5AB0A490D1D Q34140776-40D64D16-5257-4F3C-A63A-6A1EF0AE865C Q34309476-4DDC6E1B-0E42-4544-843B-DF72AB99A6B3 Q34378603-13C7237F-2022-4F96-B3B2-B8163EB79B52 Q34378825-D5BB063E-1B77-4357-8B66-DCADE0B6295C Q34409080-A0BDF57D-150B-42A6-9A2D-159CFAF16F41 Q34409644-B97185AF-EA23-45BD-838C-88FEF2240E8B Q34745082-A5E6A8B0-D2A4-4752-B101-6736FAC2ABE3 Q35010994-FD5E8D9F-A137-4BCE-BEDD-00BA9228E1C1 Q35242583-7210AEC3-C0C8-448D-B74F-027C51699E9A Q35861879-9955C01B-9ECB-42B6-95AC-D787BA0DDE64 Q36868713-B52C0439-D7BD-4102-9029-9F6C3421E9EF Q36987502-04AC316B-B056-4C06-A0F7-B03124CEB846 Q37122451-0C1996DC-67B4-4EE8-8996-80064E2ED584 Q37297683-B51E6B80-110D-481B-BDBB-8805C8E75F5E Q38072281-958C1042-74BD-4176-8DD5-FC2B354ADC0F Q38117182-66535E36-6ACD-4867-BC2C-97F0EC3CAFE0 Q38229080-D395B5DE-69F1-4B9C-8C64-2F260D67E774 Q38495078-EB3CCE82-9290-4299-93B9-14879F25F7E6 Q39414540-5E7BFEAE-FF46-4B20-BE39-4F5A1469D87E Q39444480-CD162C52-EFEF-4BAF-88D0-5D8C6E4C3644 Q39452585-32EB8B22-DAC6-4601-AB64-657EB4184D4F Q39466756-55CE59F0-D20B-43DB-A917-001A2AB6541E Q39493805-4ABC3D1D-1F13-4FD7-934D-F7A4C60EF306 Q39652351-AA69E310-CC42-4110-B247-E85AA2798B43 Q40383590-D72A5F12-8834-4D3D-95C8-2A7FE554C421 Q41482831-D3F5D0CF-AFE2-4080-BAA0-5179E0C83DC9 Q41560226-289E43D4-C3D0-43AB-B6B4-C29D94EFBCE9 Q41887448-648F3884-5EDF-4232-BBA8-BB87C4D267FE Q42498100-E381E35D-E0AA-430D-8098-D54F01B22B35 Q42591214-1A2EF8D6-35AA-410A-A5B4-99027160CB49 Q42613192-775D824E-7C62-43EF-8361-EE9BF793B2A6 Q43605879-EDF6F909-743A-4511-A47E-30914367544B Q45959599-B0A350DB-4510-49F2-974E-A63F1A7C8358 Q48167378-042DA84B-3BF9-4A46-AF83-05BA749E3EF2 Q50775992-E5183B1F-5267-45A0-8064-46487CB50658

P2860

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

http://www.wikidata.org/entity/Q35250682

description

1992 nî lūn-bûn

@nan

1992 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1992 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1992年の論文

@ja

1992年論文

@yue

1992年論文

@zh-hant

1992年論文

@zh-hk

1992年論文

@zh-mo

1992年論文

@zh-tw

1992年论文

@wuu

name

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

@ast

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

@en

type

label

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

@ast

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

@en

prefLabel

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

@ast

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

@en

P1433

Q35250682-4C87811F-7AF1-4752-B683-DD52944C3D5A

P1476

Q35250682-AFB4F719-A1AC-4D85-BB02-0A18DB08DFC8

P2093

Q35250682-3C48662C-1D3B-407D-B9A8-64E8C47A527B

Q35250682-EE89FC8C-52B6-474A-A151-AA864E6CA02D

P2860

Q35250682-149C40EA-D717-4AED-94E4-30E57A1B80E1

Q35250682-1AB2CF6B-DD3D-4768-A927-2FE4A67EFBA4

Q35250682-3DE819DC-F84E-4EAB-B0F8-B985101A6BCE

Q35250682-47EC175F-4451-40CD-86ED-2186AB695647

Q35250682-4CEB77BD-FF99-4066-A700-4E2A9C13966F

Q35250682-4D537780-42E7-4A54-B26E-4663942CBEEE

Q35250682-55396180-7292-4E72-9103-D1CE47767623

Q35250682-5C4F4D39-775D-48E5-AEC2-99F19B448816

Q35250682-60458A02-3B12-48AC-8811-20CA8A934D95

Q35250682-6B6DBD2F-E391-48C0-9B9C-1ED5DFE0D6C7

P304

Q35250682-39CCFC24-A09F-42C2-AAEB-63031B3ED2B2

P31

Q35250682-47D54F9E-5B39-45D2-8163-CB047EA9F8F6

P356

Q35250682-477ADFAF-951C-446D-B99C-0A60A1F49D9C

P407

Q35250682-7578DFFE-D92B-40E6-A6B8-6C1006444660

P433

Q35250682-6629B45B-ADC6-4E65-BB24-94CDAB587E34

P478

Q35250682-7D7A18AD-220A-4708-A95B-E89F4CD0DD7F

P577

Q35250682-43543810-2C6E-44EA-93E4-98A6E8A27651

P5875

Q35250682-BAD42D8D-A58E-4E86-95AD-6BA636843A89

P698

Q35250682-0AF681B2-9D7E-412B-8CE4-02F5EAC2E10C

P932

Q35250682-751B41DC-BDD7-4ED3-B2DA-ABEB3829413A

P356

P1433

P1476

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

@en

P2093

Bell NJ

http://www.w3.org/2001/XMLSchema#string

Hunt RH

http://www.w3.org/2001/XMLSchema#string

P2860

Cimetidine therapy for gastroesophageal reflux disease

Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring.

Treatment of reflux oesophagitis with ranitidine.

H2 antagonists in the treatment of reflux oesophagitis: can physiological studies predict the response?

Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine.

Combined therapy with cisapride and cimetidine in severe reflux oesophagitis: a double blind controlled trial

Mortality caused by stomach cancer after remote partial gastrectomy for benign conditions: 40 years of follow up of an Amsterdam cohort of 2633 postgastrectomy patients.

Cimetidine and metoclopramide in oesophageal reflux disease.

Omeprazole and ranitidine in treatment of reflux oesophagitis: double blind comparative trial.

Carcinoma of the gastric stump: risks and pathogenesis.

P304

118-124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/GUT.33.1.118

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

1992-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21808479

http://www.w3.org/2001/XMLSchema#string

P698

1346769

http://www.w3.org/2001/XMLSchema#string

P932

1373877

http://www.w3.org/2001/XMLSchema#string